Do You Think the Discontinuation Rate Is the Most Important Part of the Study?

The discontinuation rate was smaller, although not that many patients discontinued only 7% in the placebo group and 4% with spheronactone. And this was a difference of 11 patients, 11 patients who were able to take an MRA in the pateromer group more than in the Placebo group. So pateromer enabled the use of an M RA in 11 out of 400 patients. But wait a minute, in order for an MRA to reduce cardiovascular death or heart-thirty hospitalization, you have to treat 11 patients for three years to reduce one event. That's not a very cost-effective strategy.